浙江东方基因生物制品股份有限公司 独立董事提名人声明与承诺 提名人浙江东方基因生物制品股份有限公司董事会，现提名陈军泽为浙江东 方基因生物制品股份有限公司第三届董事会独立董事候选人，并已充分了解被提 名人职业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录 等情况。被提名人已书面同意出任浙江东方基因生物制品股份有限公司第三届董 事会独立董事候选人（参见该独立董事候选人声明）。提名人认为，被提名人具 备独立董事任职资格，与浙江东方基因生物制品股份有限公司之间不存在任何影 响其独立性的关系，具体声明并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、行政法规、 规章及其他规范性文件，具有五年以上法律、经济、会计、财务、管理等履行独 立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以 ...

浙江东方基因生物制品股份有限公司 独立董事候选人声明与承诺 本人陈军泽，已充分了解并同意由提名人浙江东方基因生物制品股份有限公 司董事会提名为浙江东方基因生物制品股份有限公司第三届董事会独立董事候 选人。本人公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担 任浙江东方基因生物制品股份有限公司独立董事独立性的关系，具体声明并承诺 如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-059 浙江东方基因生物制品股份有限公司 关于选举独立董事并调整专门委员会及委员的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）原独立董事李波 先生因个人工作原因，向公司董事会申请辞去公司第三届董事会独立董事职务。 内容详见公司于 2025 年 9 月 10 日在上海证券交易所网站（www.sse.com.cn）披 露的《关于独立董事辞职的公告》（公告索引-2025-048）。 调整后公司第三届董事会专门委员会成员信息如下： （1）战略与投资委员会成员：方剑秋（主任委员）、方效良、陈军泽； （4）薪酬与考核委员会成员：王晓燕（主任委员）、陈军泽、方效良。 特此公告！ 公司于近日召开第三届董事会第十五次会议，审议通过了《关于选举独立董 事并调整专门委员会及委员的议案》，现将相关情况公告如下： 经公司董事会提名，董事会提名委员会资格审查，董事会同意提名陈军泽先 生（简历附后）为公司第三届董事会独立董事候选人 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-060 浙江东方基因生物制品股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 20 日 13 点 00 分 召开地点：浙江省湖州市安吉县递铺街道阳光大道东段东方基因会议室 （五） 网络投票的系统、起止日期和投票时间。 上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 20 日 至2025 年 11 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 者重大遗漏，并对其内容 ...

Core Viewpoint - The company, Dongfang Biological (688298), announced that its subsidiary, Shanghai Wanzijian Biotechnology Co., Ltd., and Healgen Scientific LLC have recently obtained medical device product registration certificates in China, Australia, and Singapore, enhancing the product variety of its flow fluorescence technology platform and expanding the international market for respiratory triple detection products [1]. Group 1 - The company has received medical device product registration certificates for multiple products [1] - The registration enhances the variety of products available on the company's flow fluorescence technology platform [1] - The respiratory triple detection products will help expand the company's international market presence [1]

Core Points - The fentanyl concept index declined by 1.78% as of the market close on November 3, ranking among the top decliners in the concept sector [1] - Within the fentanyl sector, stocks such as Botao Bio, Enhua Pharmaceutical, and Renfu Pharmaceutical experienced significant declines, while Guoyao Modern and Guoyao Shares saw slight increases of 0.48% and 0.24% respectively [1] Market Performance - The fentanyl concept sector faced a net outflow of 0.38 billion yuan in main capital today, with six stocks experiencing net outflows [2] - Enhua Pharmaceutical led the outflows with a net capital outflow of 15.56 million yuan, followed by Guoyao Shares, Lingrui Pharmaceutical, and Wanfu Biological with outflows of 10.74 million yuan, 9.79 million yuan, and 8.30 million yuan respectively [2] - Conversely, Renfu Pharmaceutical and Botao Bio attracted net inflows of 10.87 million yuan and 1.47 million yuan respectively [2] Stock Performance - Enhua Pharmaceutical saw a decline of 2.10% with a turnover rate of 1.29% and a net outflow of 15.56 million yuan [2] - Guoyao Shares increased by 0.24% with a turnover rate of 1.19% and a net outflow of 10.74 million yuan [2] - Lingrui Pharmaceutical decreased by 0.75% with a turnover rate of 1.22% and a net outflow of 9.79 million yuan [2] - Wanfu Biological declined by 0.82% with a turnover rate of 2.26% and a net outflow of 8.30 million yuan [2] - Botao Bio experienced a significant drop of 8.32% with a turnover rate of 4.20% but had a net inflow of 1.47 million yuan [2] - Renfu Pharmaceutical decreased by 1.94% with a turnover rate of 2.56% and a net inflow of 10.87 million yuan [2]

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Group 1 - The core point of the article highlights the recent performance of Dongfang Biological, which saw a 5.15% increase in stock price, reaching 26.13 yuan per share, with a total market capitalization of 5.268 billion yuan [1] - Dongfang Biological, established on December 1, 2005, specializes in the research, production, and sales of in vitro diagnostic products, with 97.99% of its revenue coming from diagnostic reagents [1] - The company has a trading volume of 1.05 billion yuan and a turnover rate of 2.01% [1] Group 2 - From the perspective of major shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) reduced its holdings by 1.7001 million shares in the third quarter, now holding 2.8 million shares, which represents 1.39% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.2% and a one-year return of 8.7%, ranking 5437 out of 8154 and 6141 out of 8046 respectively [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 69 days, with the fund's total asset size at 5.957 billion yuan [3] Group 3 - The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has Dongfang Biological as its tenth largest holding, accounting for 2.98% of the fund's net value [4] - The fund's floating profit from its investment in Dongfang Biological is approximately 3.584 million yuan [4]

Group 1 - Oriental Bio (688298.SH) reported its Q3 2025 results on October 31, 2025, with a total of 7 institutional investors holding A-shares, amounting to 104 million shares, which represents 51.44% of the total share capital [1] - The institutional investors include companies such as Anji Fulanglai Import and Export Trade Co., Ltd., Fangs Holdings Limited Liability Company, and several funds from China Industrial Bank and China Merchants Bank [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 1.23 percentage points [1] Group 2 - In the public fund sector, one fund, the Medical Device ETF, increased its holdings by 0.21% compared to the previous period [2] - One fund, the Rongtong Health Industry Flexible Allocation Mixed A/B, reduced its holdings by 0.84% compared to the previous quarter [2] - A total of 63 public funds did not disclose their holdings this period, including funds like Yuanxin Yongfeng Ju You A and Rongtong Value Growth Mixed A [2]

Core Viewpoint - On October 30, 2025, the company will hold the 15th meeting of the third board of directors to review the proposal regarding the confirmation of the audit committee members and the nomination of the convener [2] Group 1 - The company announced the date for the upcoming board meeting [2] - The agenda includes the confirmation of audit committee members [2] - The proposal also involves the nomination of the convener for the audit committee [2]